Researchers reported a novel infection‑prevention approach that demonstrated simultaneous blockade of drug‑resistant bacterial pathogens and influenza virus in preclinical tests. The study, summarized in the article, claims the method prevented secondary infections that complicate severe respiratory disease and can be especially lethal in immunocompromised or hospitalized patients. The approach combines antimicrobial and antiviral modalities to reduce co‑infection risk factors. The authors position the technology as a platform to lower hospital‑acquired infection rates and blunt the impact of rising antimicrobial resistance, though details on mechanism, model systems and translational readiness were limited in the summary. Broad‑spectrum infection prevention aims to reduce multiple pathogen types at the point of exposure or early replication, potentially lowering morbidity in at‑risk populations.